| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
SIRT3
The primary targets of 5-Heptadecylresorcinol include sirtuin3, mitochondrial function, and autophagy pathways. It improves mitochondrial function via the sirtuin3 signaling pathway, thus alleviating endothelial cell damage and apoptosis. The compound induces sirtuin3-mediated autophagy. It shows strong inhibitory property against the growth of PC3 cells. It also exhibits anti-inflammatory, anti-carcinogenic, and anti-microbial bioactivities. |
|---|---|
| ln Vitro |
5-Heptadecylresorcinol boosts SIRT3 in HUVECs [1] to reduce mitochondrial dysfunction at 0, 0.5, 1, and 2 µM during a 24-hour period. 5-Heptadecylresorcinol reduces mitochondrial damage and adipocyte lipolysis brought on by inflammatory conditioned medium (CM), while also reducing the generation of reactive oxygen species inside the mitochondria and the depolarization of the mitochondrial membrane [2]. By decreasing the release of glycerol from 3T3-L1 adipocytes, 5-Heptadecylresorcinol (5, 10 and 15 μM; 24 hours) significantly inhibits CM-induced lipolysis in adipocytes [2]. 5-Adipocytes with CM-induced mitochondrial dysfunction are improved by 5-Heptadecylresorcinol (5, 10 and 15 μM; 24 hours) [2].
In vitro, 5-Heptadecylresorcinol improves mitochondrial function via the sirtuin3 signaling pathway, thus alleviating endothelial cell damage and apoptosis. It induces sirtuin3-mediated autophagy. The compound shows strong inhibitory property against the growth of PC3 cells. It exhibits anti-inflammatory, anti-carcinogenic, and anti-microbial bioactivities. |
| ln Vivo |
5-Heptadecylresorcinol (30 mg/kg, 150 mg/kg; taken orally daily for 16 weeks) enhances lipid metabolism in mice fed a high-fat diet that are ApoE−/− [1]. 5-Heptadecylresorcinol improves body weight and decreases mitochondrial dysfunction and adipose tissue macrophage infiltration in mice when given orally every day for 16 weeks (30 mg/kg, 150 mg/kg) [2].
In vivo activity of 5-Heptadecylresorcinol has not been extensively characterized. As a natural phenol with anti-inflammatory, anti-carcinogenic, and anti-microbial activities, it has potential therapeutic applications. However, detailed in vivo pharmacokinetic and pharmacodynamic studies are limited. The compound is primarily studied for its in vitro activities. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 5-Heptadecylresorcinol are not well established, as the compound is primarily studied for its effects on mitochondrial function and autophagy. Quality control assays involve HPLC to verify purity (≥98+%) and identity. The compound is tested for solubility and stability under standard storage conditions. It is intended for use as an analytical reference standard for quantification in various matrices.
|
| Cell Assay |
Western Blot Analysis[2]
Cell Types: 3T3-L1 adipocytes Tested Concentrations: 5, 10 and 15 μM Incubation Duration: 24 hrs (hours) Experimental Results: Increased the expression of UCP1, COX IV, PGC-1α, DRP1 and MFN2 proteins. In vitro cellular assays for 5-Heptadecylresorcinol involve testing its effects on mitochondrial function, autophagy, and cell viability. Endothelial cells or cancer cells (e.g., PC3 cells) are treated with varying concentrations of 5-Heptadecylresorcinol (0.1-100 µM) for 24-72 hours. Mitochondrial function is assessed by measuring ATP levels and oxygen consumption. Autophagy is assessed by LC3-II accumulation. Cell viability is assessed using MTT or CCK-8 assays. The compound improves mitochondrial function and induces autophagy. |
| Animal Protocol |
Animal/Disease Models: C57BL/6J mice[1][2]
Doses: 30 mg/kg, 150 mg/kg Route of Administration: PO; daily for 16 weeks Experimental Results: Lowered serum total cholesterol, triglyceride, VLDL-C, and LDL-C levels[1]. diminished adipose tissue macrophage infiltration from high-fat diet induced obese C57BL/6J mice[2]. In vivo animal studies for 5-Heptadecylresorcinol are limited, as the compound is primarily studied in vitro. For efficacy testing, animal models of disease could be used. Animals would be treated with the compound via oral administration at various doses, and relevant biomarkers would be assessed. However, detailed in vivo protocols are not well established in the available literature. |
| ADME/Pharmacokinetics |
5-Heptadecylresorcinol has a molecular formula of C23H40O2 and a molecular weight of 348.56. It appears as a solid with a purity of 98+%. It is a natural phenol found in the herbs of Mangifera indica. The compound may be used as an analytical reference standard for the quantification of the analyte in mango peels, rye grains, and agricultural products using different chromatography techniques. It is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 5-Heptadecylresorcinol has not been extensively characterized. As a natural product, it is generally considered to have low toxicity. Standard toxicity studies would include assessment of acute oral toxicity, dermal irritation, and repeated-dose toxicity in animal models. The compound is intended for research use only and is not approved for clinical use.
|
| References |
|
| Additional Infomation |
5-Heptadecanylresorcinol is a 5-alkylresorcinol, where resorcinol is replaced by a heptadecanyl group at the 5-position. It is found in wheat bran. It has antitumor activity and is also a plant metabolite. 5-Heptadecanylbenzene-1,3-diol has been reported to be found in barley (Hordeum vulgare), rye (Secale cereale), and other organisms with relevant data.
5-Heptadecylresorcinol (CAS 41442-57-3) is a natural phenol found in the herbs of Mangifera indica. It has a molecular formula of C23H40O2 and a molecular weight of 348.56. The compound improves mitochondrial function via the sirtuin3 signaling pathway, alleviates endothelial cell damage and apoptosis, and induces sirtuin3-mediated autophagy. It shows strong inhibitory activity against PC3 cells and exhibits anti-inflammatory, anti-carcinogenic, and anti-microbial properties. It is intended for research use only and is not approved for clinical use. |
| Molecular Formula |
C23H40O2
|
|---|---|
| Exact Mass |
348.302
|
| CAS # |
41442-57-3
|
| PubChem CID |
181700
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
478.0±15.0 °C at 760 mmHg
|
| Melting Point |
91 - 93 °C
|
| Flash Point |
202.6±15.0 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.507
|
| LogP |
9.72
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
25
|
| Complexity |
269
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
BBGNINPPDHJETF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H40O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21-18-22(24)20-23(25)19-21/h18-20,24-25H,2-17H2,1H3
|
| Chemical Name |
5-heptadecylbenzene-1,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
